204906 | Complement C5b,6 Complex, Human

204906
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      204906-50UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 50 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8, and C9 to form the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8, and C9.
          Catalogue Number204906
          Brand Family Calbiochem®
          References
          ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
          Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
          Product Information
          FormLiquid
          FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Specific Activity≥2000 C5b,6H50 units/mg
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          204906

          References

          Reference overview
          Podack, E.R., et al. 1978. J. Immunol. 120, 1841.
          Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-May-2008 RFH
          DescriptionNative, human C5b,6 complement component complex. Activation of complement by either pathway results in the formation of C5-cleaving enzymes (C5 convertases) on target surfaces. The C5 convertase enzymes cleave the C5 α-chain at peptide bond 74, resulting in the formation of the C5a anaphylatoxin (M.W. 11,200) and the C5b fragment (M.W. 185,000). The nascent C5b fragment can combine with C6, C7, C8 and C9 to from the lytic C5b-9 membrane attack complex on target surfaces. When C5 activation occurs in the presence of C6 only, e.g. in C7 deficient serum, a stable C5b,6 complex is formed. In a process termed Reactive Lysis, the membrane attack complex can be assembled on target cell surfaces in the absence of any additional complement proteins by incubating target cells with the C5b,6 complex and purified C7, C8 and C9.
          FormLiquid
          FormulationIn 120 mM NaCl, 10 mM HEPES, pH 7.2.
          Concentration Label Please refer to vial label for lot-specific concentration
          SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Purity≥95% by SDS-PAGE
          Specific activity≥2000 C5b,6H50 units/mg
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesPodack, E.R., et al. 1978. J. Immunol. 120, 1841.
          Lachmann, P.J. and Thompson, R.A. 1970. J. Exp. Med. 131, 643.